Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute coronary syndromes: 2. Antiplatelet agents

D J Schneider1, P B Tracy, B E Sobel

  • 1Department of Medicine, University of Vermont School of Medicine, Burlington, USA.

Hospital Practice (1995)
|June 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers, surrogates, and evaluation of therapeutic agents: a proposed solution.

Coronary artery disease·1999
Same author

The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.

Proceedings of the Association of American Physicians·1999
Same author

Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications.

Thrombosis research·1999
Same author

Insulin resistance and thrombosis: a cardiologist's view.

The American journal of cardiology·1999
Same author

TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes.

The American journal of physiology·1999
Same author

Cardiovascular consequences of polycystic ovary syndrome.

Endocrinology and metabolism clinics of North America·1999

Novel antiplatelet and anticoagulant therapies are revolutionizing acute coronary syndrome management. These agents, alongside fibrinolytic drugs and mechanical interventions, prevent thrombin generation by activated platelets.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) management relies on preventing thrombotic events.
  • Platelet activation plays a critical role in thrombus formation in ACS.

Purpose of the Study:

  • To review current research on novel antiplatelet and anticoagulant therapies.
  • To highlight the impact of these agents on ACS management.

Main Methods:

  • Literature review of recent studies on antiplatelet and anticoagulant agents.
  • Analysis of therapeutic strategies combining novel agents with existing treatments.

Main Results:

  • Novel antiplatelet and anticoagulant agents effectively inhibit thrombin generation.
  • Combination therapies show promise in enhancing ACS treatment outcomes.

Related Experiment Videos

Conclusions:

  • New antiplatelet and anticoagulant therapies represent a significant advancement in ACS care.
  • Judicious use of these agents, with fibrinolytic drugs and mechanical interventions, is transforming patient management.